LungQ™ Clinical Suite

Aiding clinical specialists in best possible patient care

Intelligent AI-powered analysis of thoracic CT scans, developed for specialized clinical trials and interventional pulmonology, is now available as a reliable and user-friendly application for clinical use. LungQ™ Clinical Suite enables efficient workflows in diagnosis and treatment planning for the most common diseases such as Asthma, COPD and Bronchiectasis. It also provides statistically powerful insights for tackling rare and complex conditions, such as Cystic Fibrosis and Idiopathic Pulmonary Fibrosis.

Use cases

Emphysema and fissure completeness in COPD

LungQ’s COPD module provides quantitative analysis of the extent and distribution of lung emphysema and fissure completeness. These assessments support clinical decision making and accurate referral of late-stage COPD patients. For specialized interventional pulmonologists, emphysema and fissure assessment supports treatment planning and allows targeted intervention.

LungQ’s COPD module builds on Thirona’s expertise in interventional pulmonology, providing measurements that are being used at more than 300 hospitals for treatment planning support.

Certified for Europe. FDA 510(k) cleared.

COVID-19 severity assessment for diagnostic support

LungQ’s COVID-19 module provides a quantitative assessment of COVID-19 infection severity in the lung. Percentages of affected lung area relate to the severity and stage of disease, supporting fast and accurate diagnosis and treatment decisions. Quantitative, anatomically precise assessments are valuable for objective monitoring of disease progression and recovery.

LungQ’s COVID-19 module is an integrated version of CAD4COVID-CT, which has contributed to diagnosis of COVID-19 on more than 10,000 CT scans of patients in 30 countries worldwide.

Certified for Europe. FDA permitted the software to be used in the USA. Not available for sale in the USA.

Airway disease assessment for Bronchiectasis

LungQ’s Bronchiectasis module provides a detailed assessment of airway abnormalities. The quantification and localization of abnormally enlarged airways support severity assessment of Bronchiectasis in patients with underlying lung conditions, including infectious diseases and Cystic Fibrosis. Early diagnosis of Bronchiectasis contributes to disease management and in-depth assessment helps to make informed treatment decisions and monitor disease progression.

LungQ’s Bronchiectasis module has been extensively validated in clinical research together with pulmonologists at Erasmus Medical Center Rotterdam.

CE approval pending.

CAD4COVID


PLEASE BE NOTIFIED

The CAD4COVID-CT software to screen for COVID-19, initially offered as a stand alone package, will soon be available for clinical use through a LungQ™ Clinical Suite.

More on CAD4COVID

Interested in a clinical integration?


Having built solid domain expertise and a strong AI-powered technology backbone, we are now
making the tools available to all clinical users through partnerships and integrations.

Let's explore the partnership opportunities!

Carla Kalkhoven

Business development manager for clinical care

Get in touch!

Interested in a clinical integration?


Having built solid domain expertise and a strong AI-powered technology backbone, we are now making the tools available to all clinical users through partnerships and integrations.

Let's explore the partnership opportunities!

Carla Kalkhoven

Business development manager for clinical care

Get in touch!